Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
|Articles|January 6, 2021
The Top 5 Skin Cancer News and Updates That Patients May Have Missed in 2020
Author(s)CURE staff
Listen
0:00 / 0:00
Key Takeaways
- Circulating tumor cells in stage 3 melanoma patients serve as a biomarker for relapse, aiding treatment strategies.
- Tafinlar and Mekinist achieved over 50% relapse-free survival in BRAF V600E/K-mutant melanoma, per COMBI-AD trial results.
A roundup of some skin cancer news and updates that occurred in 2020 that patients may have missed.
Advertisement
There were several updates in the field of skin cancer in 2020. Here, CURE® looks back at some of the most-read news and updates in the field of skin cancer that patients may have missed.
- Patients with stage 3 melanoma who had one or more circulating tumor cells were found to relapse sooner, providing physicians with an important biomarker to treat the likelihood of relapse.
READ MORE .
- Adjuvant Tafinlar (dabrafenib) and Mekinist (trametinib) elicited a greater than 50% relapse-free survival (RFS) rate in patients with resected, stage 3 BRAF V600E/K-mutant melanoma, according to findings from a five-year analysis of the phase 3 COMBI-AD trial.
READ MORE . - A personalized vaccine has demonstrated long-term disease-free and overall survival benefits in patients with stage 3 or stage 4 melanoma at a high risk of recurrence following complete surgical resection, according to the vaccine’s manufacturer, Elios Therapeutics.
READ MORE . - Patients appear open to the idea of using artificial intelligence (AI) to help in screening for skin cancer, however many patients stress the need to preserve the patient-physician relationship if implemented, according to study results published in JAMA Dermatology.
READ MORE . - Following a median follow-up of three years, the use of immunotherapy agent Keytruda (pembrolizumab) for the adjuvant treatment of patients with resected, high-risk, stage 3 melanoma demonstrated a sustained and clinical meaningful improvement in recurrence-free survival (RFS), compared with placebo.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.
Advertisement
Advertisement
Trending on CURE
1
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
2
Top 5 Takeaways From ESMO 2026 That Patients Should Know
3
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
4
4 Lung Cancer Results From ESMO 2026 Patients Should Know
5